molecules-logo

Journal Browser

Journal Browser

Reactive Oxygen Species-Based Dynamic Therapy of Cancer

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Medicinal Chemistry".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 13649

Special Issue Editors


E-Mail Website
Guest Editor
School of Biomedical Engineering, Research and Engineering Center of Biomedical Materials, Anhui Provincial Institute of Translational Medicine, Anhui Medical University, Hefei 230032, China
Interests: photothermal therapy; photodynamic therapy; sonodynamic therapy; chemotherapy; cancer theranostics

E-Mail Website
Guest Editor
Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, The First School of Clinical Medicine, Southern Medical University, Guangzhou 510515, China
Interests: nanomedicine; biomaterials
School of Medicine, South China University of Technology, Guangzhou 510006, Guangdong, China
Interests: photothermal therapy; photodynamic therapy; sonodynamic therapy; chemotherapy; cancer theranostics

Special Issue Information

Dear Colleagues,

Reactive oxygen species (ROS)-related therapies by in situ ROS generation are emerging as an attractive therapeutic modality with potential to treat deep-seated tumors, avoiding side effects to healthy tissues. Nanomedicine, which can be designed with unique physicochemical properties, can respond to external excitations such as near-infrared (NIR) light, ultrasound (US), X-ray, and microwave (MW), or trigger internal chemical/biological reaction in tumor region to produce ROS for ROS-related therapies, showing great advantages for deep-seated tumor treatment with high specificity, safety, and non-invasiveness. 

Although ROS-related therapies have made positive progress in tumor treatment, there are still many limitations. In this research topic, we aim to cover the latest research on functional biomaterials with unique capabilities for ROS-related cancer therapy

We cordially welcome investigators to submit articles (original research, review). Potential topics include, but are not limited to:

  • Design and preparation of functional biomaterials for ROS-related cancer therapy;
  • Killing mechanism of ROS-related therapy;
  • Toxicology studies on ROS-induced biomaterials.

Dr. Xianwen Wang
Dr. Daoming Zhu
Dr. Zhijin Fan
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • reactive oxygen species
  • cancer therapy
  • photodynamic therapy
  • sonodynamic therapy
  • chemodynamic therapy
  • tumor microenvironment
  • biomaterials

Published Papers (6 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 1851 KiB  
Article
Lipopolysaccharide Activated NF-kB Signaling by Regulating HTRA1 Expression in Human Retinal Pigment Epithelial Cells
by Shengliu Pan, Min Liu, Huijuan Xu, Junlan Chuan and Zhenglin Yang
Molecules 2023, 28(5), 2236; https://doi.org/10.3390/molecules28052236 - 28 Feb 2023
Cited by 4 | Viewed by 1852
Abstract
Inflammation and elevated expression of high temperature requirement A serine peptidase 1 (HTRA1) are known high risk factors for age-related macular degeneration (AMD). However, the specific mechanism that HTRA1 causes AMD and the relationship between HTRA1 and inflammation remains unclear. We found that [...] Read more.
Inflammation and elevated expression of high temperature requirement A serine peptidase 1 (HTRA1) are known high risk factors for age-related macular degeneration (AMD). However, the specific mechanism that HTRA1 causes AMD and the relationship between HTRA1 and inflammation remains unclear. We found that lipopolysaccharide (LPS) induced inflammation enhanced the expression of HTRA1, NF-κB, and p-p65 in ARPE-19 cells. Overexpression of HTRA1 up-regulated NF-κB expression, and on the other hand knockdown of HTRA1 down-regulated the expression of NF-κB. Moreover, NF-κB siRNA has no significant effect on the expression of HTRA1, suggesting HTRA1 works upstream of NF-κB. These results demonstrated that HTRA1 plays a pivotal role in inflammation, explaining possible mechanism of overexpressed HTRA1-induced AMD. Celastrol, a very common anti-inflammatory and antioxidant drug, was found to suppress inflammation by inhibiting phosphorylation of p65 protein efficaciously in RPE cells, which may be applied to the therapy of age-related macular degeneration. Full article
(This article belongs to the Special Issue Reactive Oxygen Species-Based Dynamic Therapy of Cancer)
Show Figures

Figure 1

9 pages, 2862 KiB  
Article
Microfluidic Synthesis of the Tumor Microenvironment-Responsive Nanosystem for Type-I Photodynamic Therapy
by Chunyu Huang, Mingzhu Chen, Liang Du, Jingfeng Xiang, Dazhen Jiang and Wei Liu
Molecules 2022, 27(23), 8386; https://doi.org/10.3390/molecules27238386 - 1 Dec 2022
Cited by 5 | Viewed by 1931
Abstract
Type I photosensitizers with aggregation-induced emission luminogens (AIE-gens) have the ability to generate high levels of reactive oxygen species (ROS), which have a good application prospect in cancer photodynamic therapy (PDT). However, the encapsulation and delivery of AIE molecules are unsatisfactory and seriously [...] Read more.
Type I photosensitizers with aggregation-induced emission luminogens (AIE-gens) have the ability to generate high levels of reactive oxygen species (ROS), which have a good application prospect in cancer photodynamic therapy (PDT). However, the encapsulation and delivery of AIE molecules are unsatisfactory and seriously affect the efficiency of a practical therapy. Faced with this issue, we synthesized the metal-organic framework (MOF) in one step using the microfluidic integration technology and encapsulated TBP-2 (an AIE molecule) into the MOF to obtain the composite nanomaterial ZT. Material characterization showed that the prepared ZT had stable physical and chemical properties and controllable size and morphology. After being endocytosed by tumor cells, ZT was degraded in response to the acidic tumor microenvironment (TME), and then TBP-2 molecules were released. After stimulation by low-power white light, a large amount of •OH and H2O2 was generated by TBP-2 through type I PDT, thereby achieving a tumor-killing effect. Further in vitro cell experiments showed good biocompatibility of the prepared ZT. To the best of our knowledge, this report is the first on the microfluidic synthesis of multifunctional MOF for type I PDT in response to the TME. Overall, the preparation of ZT by the microfluidic synthesis method provides new insight into cancer therapy. Full article
(This article belongs to the Special Issue Reactive Oxygen Species-Based Dynamic Therapy of Cancer)
Show Figures

Figure 1

10 pages, 2560 KiB  
Article
A Polyoxometalate-Encapsulated Metal–Organic Framework Nanoplatform for Synergistic Photothermal–Chemotherapy and Anti-Inflammation of Ovarian Cancer
by Diqing Wang, Yuqi Wang, Xinyu Zhang, Qian Lv, Guiqi Ma, Yuan Gao, Shuangqing Liu, Chenyu Wang, Changzhong Li, Xiao Sun and Jipeng Wan
Molecules 2022, 27(23), 8350; https://doi.org/10.3390/molecules27238350 - 30 Nov 2022
Cited by 7 | Viewed by 1631
Abstract
Photothermal therapy (PTT), as a noninvasive and local treatment, has emerged as a promising anti-tumor strategy with minimal damage to normal tissue under spatiotemporally controllable irradiation. However, the necrosis of cancer cells during PTT will induce an inflammatory reaction, which may motivate tumor [...] Read more.
Photothermal therapy (PTT), as a noninvasive and local treatment, has emerged as a promising anti-tumor strategy with minimal damage to normal tissue under spatiotemporally controllable irradiation. However, the necrosis of cancer cells during PTT will induce an inflammatory reaction, which may motivate tumor regeneration and resistance to therapy. In this study, polyoxometalates and a chloroquine diphosphate (CQ) co-loaded metal–organic framework nanoplatform with hyaluronic acid coating was constructed for efficient ovarian cancer therapy and anti-inflammation. Our results demonstrated that this nanoplatform not only displayed considerable photothermal therapeutic capacity under 808 nm near-infrared laser, but also had an impressive anti-inflammatory capacity by scavenging reactive oxygen species in the tumor microenvironment. CQ with pH dependence was used for the deacidification of lysosomes and the inhibition of autophagy, cutting off a self-protection pathway induced by cell necrosis–autophagy, and achieving the synergistic treatment of tumors. Therefore, we combined the excellent properties of these materials to synthesize a nanoplatform and explored its therapeutic effects in various aspects. This work provides a promising novel prospect for PTT/anti-inflammation/anti-autophagy combinations for efficient ovarian cancer treatment through the fine tuning of material design. Full article
(This article belongs to the Special Issue Reactive Oxygen Species-Based Dynamic Therapy of Cancer)
Show Figures

Figure 1

10 pages, 1804 KiB  
Article
Maleimide-Functionalized Liposomes: Prolonged Retention and Enhanced Efficacy of Doxorubicin in Breast Cancer with Low Systemic Toxicity
by Chuane Tang, Dan Yin, Tianya Liu, Rui Gou, Jiao Fu, Qi Tang, Yao Wang, Liang Zou and Hanmei Li
Molecules 2022, 27(14), 4632; https://doi.org/10.3390/molecules27144632 - 20 Jul 2022
Cited by 6 | Viewed by 2059
Abstract
Cell surface thiols can be targeted by thiol-reactive groups of various materials such as peptides, nanoparticles, and polymers. Here, we used the maleimide group, which can rapidly and covalently conjugate with thiol groups, to prepare surface-modified liposomes (M-Lip) that prolong retention of doxorubicin [...] Read more.
Cell surface thiols can be targeted by thiol-reactive groups of various materials such as peptides, nanoparticles, and polymers. Here, we used the maleimide group, which can rapidly and covalently conjugate with thiol groups, to prepare surface-modified liposomes (M-Lip) that prolong retention of doxorubicin (Dox) at tumor sites, enhancing its efficacy. Surface modification with the maleimide moiety had no effect on the drug loading efficiency or drug release properties. Compared to unmodified Lip/Dox, M-Lip/Dox was retained longer at the tumor site, it was taken up by 4T1 cells to a significantly greater extent, and exhibited stronger inhibitory effect against 4T1 cells. The in vivo imaging results showed that the retention time of M-Lip at the tumor was significantly longer than that of Lip. In addition, M-Lip/Dox also showed significantly higher anticancer efficacy and lower cardiotoxicity than Lip/Dox in mice bearing 4T1 tumor xenografts. Thus, the modification strategy with maleimide may be useful for achieving higher efficient liposome for tumor therapy. Full article
(This article belongs to the Special Issue Reactive Oxygen Species-Based Dynamic Therapy of Cancer)
Show Figures

Figure 1

12 pages, 1322 KiB  
Article
Aptamer-Functionalized Iron-Based Metal–Organic Frameworks (MOFs) for Synergistic Cascade Cancer Chemotherapy and Chemodynamic Therapy
by Xuan Wang, Qing Chen and Congxiao Lu
Molecules 2022, 27(13), 4247; https://doi.org/10.3390/molecules27134247 - 30 Jun 2022
Cited by 9 | Viewed by 2352
Abstract
Hypoxia-activated prodrugs (HAPs) with selective toxicity in tumor hypoxic microenvironments are a new strategy for tumor treatment with fewer side effects. Nonetheless, the deficiency of tumor tissue enrichment and tumor hypoxia greatly affect the therapeutic effect of HAPs. Herein, we design an active [...] Read more.
Hypoxia-activated prodrugs (HAPs) with selective toxicity in tumor hypoxic microenvironments are a new strategy for tumor treatment with fewer side effects. Nonetheless, the deficiency of tumor tissue enrichment and tumor hypoxia greatly affect the therapeutic effect of HAPs. Herein, we design an active targeted drug delivery system driven by AS1411 aptamer to improve the tumor tissue enrichment of HAPs. The drug delivery system, called TPZ@Apt-MOF (TA-MOF), uses iron-based MOF as a carrier, surface-modified nucleolin aptamer AS1411, and the internal loaded hypoxia activation prodrug TPZ. Compared with naked MOF, the AS1411-modified MOF showed a better tumor targeting effect both in vitro and in vivo. MOF is driven by GSH to degrade within the tumor, producing Fe2+, and releasing the cargo. This process leads to a high consumption of the tumor protective agent GSH. Then, the Fenton reaction mediated by Fe2+ not only consumes the intracellular oxygen but also increases the intracellular production of highly toxic superoxide anions. This enhances the toxicity and therapeutic effect of TPZ. This study provides a new therapeutic strategy for cancer treatment. Full article
(This article belongs to the Special Issue Reactive Oxygen Species-Based Dynamic Therapy of Cancer)
Show Figures

Figure 1

Review

Jump to: Research

14 pages, 2735 KiB  
Review
Current Strategies for Modulating Tumor-Associated Macrophages with Biomaterials in Hepatocellular Carcinoma
by Qiaoyun Liu, Wei Huang, Wenjin Liang and Qifa Ye
Molecules 2023, 28(5), 2211; https://doi.org/10.3390/molecules28052211 - 27 Feb 2023
Cited by 3 | Viewed by 2135
Abstract
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related deaths in the world. However, there are currently few clinical diagnosis and treatment options available, and there is an urgent need for novel effective approaches. More research is being undertaken on immune-associated [...] Read more.
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related deaths in the world. However, there are currently few clinical diagnosis and treatment options available, and there is an urgent need for novel effective approaches. More research is being undertaken on immune-associated cells in the microenvironment because they play a critical role in the initiation and development of HCC. Macrophages are specialized phagocytes and antigen-presenting cells (APCs) that not only directly phagocytose and eliminate tumor cells, but also present tumor-specific antigens to T cells and initiate anticancer adaptive immunity. However, the more abundant M2-phenotype tumor-associated macrophages (TAMs) at tumor sites promote tumor evasion of immune surveillance, accelerate tumor progression, and suppress tumor-specific T-cell immune responses. Despite the great success in modulating macrophages, there are still many challenges and obstacles. Biomaterials not only target macrophages, but also modulate macrophages to enhance tumor treatment. This review systematically summarizes the regulation of tumor-associated macrophages by biomaterials, which has implications for the immunotherapy of HCC. Full article
(This article belongs to the Special Issue Reactive Oxygen Species-Based Dynamic Therapy of Cancer)
Show Figures

Figure 1

Back to TopTop